ALERT: Due to the inclement weather across much of the country, Medtronic deliveries are currently experiencing delays and there will be longer than normal hold times on the phone. Visit if you need to place an order, get a sensor or belt clip replacement, or check the status of your supply order. X

News Releases

CMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps

December 22, 2021

Medicare coverage for Medtronic customers will be available 60 days after official publication

DUBLIN, Dec. 22, 2021 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes CGMs that integrate with Medtronic insulin pumps. The proposed rule was finalized on December 21, 2021 and will be effective starting 60 days after official publication.

Read more >

Medtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with Diabetes

April 7, 2021

New Partnerships and Research Efforts Prioritized Over the Next Three Years to Address Health Disparities

April 7, 2021 - MINNEAPOLIS, /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association® (ADA) and T1D Exchange, as well as additional research efforts, to better understand and address these disparities.

Read more >

Medtronic Commends CMS on Proposed Rule to Expand Medicare Coverage for All CGMs

October 28, 2020

October 28, 2020 – On October 27th, the Centers for Medicare & Medicaid Services (CMS) announced proposed new changes that, if finalized, would expand Medicare coverage for Continuous Glucose Monitors (CGMs) that provide critical information on glucose levels to help people with diabetes better manage their disease. We are very encouraged by CMS’s proposed rule and commend the agency on taking action to help more people with diabetes.

Read more >

Medtronic Announces FDA Approval for MiniMed™ 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes

September 1, 2020

DUBLIN – September 1, 2020 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system. This newest insulin pump system offers the company’s most advanced SmartGuard™ technology, as featured in the MiniMed™ 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.

Read more >

Medtronic Plans To Acquire Smart Insulin Pen Company Companion Medical

August 11, 2020

DUBLIN and SAN DIEGO – August 11, 2020 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA cleared smart insulin pen system paired with an integrated diabetes management app on the market. The addition of Companion Medical’s InPen to the Medtronic portfolio expands the company’s ability to serve people where they are in their diabetes journey and offer them a unique and expansive ecosystem of support — regardless of how insulin is delivered.

Read more >

View all Announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Cho
Sr Director, Global Communications

Pamela Reese
Director, Communications

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits